Trade JnJ ^JNJ

Johnson & Johnson $JNJ Shares Sold by Brookstone Capital Management

Johnson & Johnson $JNJ Stock: Boomfish Wealth Group LLC Cuts Stake

Johnson & Johnson Posts Positive Phase 1b/2 Data Of Amivantamab Combo In Head And Neck Cancer

Promising Results from Johnson & Johnson's New Prostate Cancer Drug, ETPharma

Johnson & Johnson announces Phase 1 results for JNJ-6143 at ESMO 2026

Johnson & Johnson announces results from Cohort 5 of Phase 1b/2 OrigAMI-4 study

Johnson & Johnson announces results from Phase 3 PROTEUS substudy

T-Bills Yield Up to 4.45%. Why Would Retirees Choose Dividend Stocks?

Promising Healthcare Stocks To Keep An Eye On - October 25th - Markets Daily

Smith & Nephew (LSE:SN.) Stays Independent, Is It 8% Undervalued?

J&J's RYBREVANT FASPRO Regimen Delivers 77% Response Rate In First-Line HNSCC Study

Smith & Nephew (LSE:SN.) Stock May Be 34% Below Fair Value As Merger Talks Collapse

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer | Morningstar

Johnson & Johnson (JNJ) Reports 69% Tumor Response Rate for Prostate Cancer Drug

7,129 Johnson & Johnson $JNJ Shares Sold by Smith Chas P & Associates PA Cpas

23,454 Johnson & Johnson $JNJ Shares Sold by Vest Financial LLC

Johnson & Johnson $JNJ Stock Sold by Investment House LLC

Johnson & Johnson $JNJ Stock: Lmcg Investments LLC Decreases Stake - Stock Observer

SBI Securities Co. Ltd. Acquires 10,021 Shares of Johnson & Johnson $JNJ - Daily Political

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer | Valuespectrum.com

Johnson & Johnson (NYSE:JNJ) Stock Price Up 3.8% - What's Next?

Johnson & Johnson $JNJ Shares Newly Bought by Sawyer & Company Inc

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Johnson & Johnson $JNJ Stock Sold by Crossmark Global Holdings Inc.

Johnson & Johnson $JNJ Stock Holdings Cut by Cooke & Bieler LP

39,667 Johnson & Johnson $JNJ Shares Sold by Axxcess Wealth Management LLC

Johnson & Johnson (NYSE:JNJ) Stock Now Rated "Moderate Buy" by Wall Street Analysts

Wavvest Wealth LLC Purchases New Position in Johnson & Johnson $JNJ - Daily Political

2,062 Johnson & Johnson $JNJ Shares Sold by Sowell Financial Services LLC - Daily Political

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer | Valuespectrum.com

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial

Johnson & Johnson (NYSE:JNJ) Shares Down 1.3% - Here's What Happened

Promising Healthcare Stocks To Consider - October 23rd - Stock Observer

JNJ Gets European Approval For TECVAYLI Monotherapy To Treat Relapsed/refractory Multiple Myeloma

UK approves J&J's oral psoriasis pill

Johnson & Johnson (JNJ) Sees $54.1 Million in Net ETF Selling on Oct. 21

QV Investors Inc. Sells 3,960 Shares of Johnson & Johnson $JNJ - Zolmax

Johnson & Johnson $JNJ Stock Sold by Nisa Investment Advisors LLC

Johnson & Johnson $JNJ Stock: QV Investors Inc. Reduces Holdings - Daily Political

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Market Poised for Substantial Growth Through 2034, Reports DelveInsight | ABNewswire

Johnson & Johnson (NYSE:JNJ) Shares Up 3.8% - Still a Buy?

Procter & Gamble Jumps 6% as Earnings Beat Draws Defensive Buyers; Johnson & Johnson Rises 3%, Coca-Cola Ticks Up

Johnson & Johnson Deepens its Long-Term Commitment to Hong Kong Through OASES Strategic Enterprise Collaboration | Macau Business

Johnson & Johnson (NYSE:JNJ) Shares Up 2.2% - Time to Buy?

JNJ Stock Has a New Growth Story, but One Business Needs to Catch Up

The International Myeloma Foundation Launches US Myeloma Network to Accelerate Clinical Trials, Expand Access, and Improve Patient Care | Morningstar

Social Security Isn't Enough: 5 Secure Dividend Stocks to Fund Your Retirement

Hong Kong attracts another 18 strategic firms, HK$10 billion in investment pledged

Top Pharmaceutical Stocks To Add to Your Watchlist - October 22nd - Daily Political

Johnson & Johnson $JNJ Stock: Willis Investment Counsel Cuts Position - Zolmax

7,115 Johnson & Johnson $JNJ Shares Bought by Sumitomo Mitsui DS Asset Management Company Ltd - Markets Daily

JNJ: Drug Strength Supports The Story, MedTech And 2027 Dilution Cap Upside

Johnson & Johnson $JNJ Shares Sold by Willis Investment Counsel - Daily Political

Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?

Johnson & Johnson (JNJ) Drugs Lift Guidance, but Is 23 Times Earnings Fair?

Top Pharmaceutical Stocks Worth Watching - October 21st - Zolmax

Treasury Yields Are Near 5%. Should Retirees Rethink Dividend Stocks?

Johnson & Johnson's Profit Fell 96% Year-Over-Year. But the Dividend Has Risen for 64 Years in a Row

Washburn Capital Management Inc. Makes New Investment in Johnson & Johnson $JNJ

Global Life Science Market Report 2026: Size, Trends and Forecast to 2030 | Secure $200.6B AI and Precision Medicine Upside with Johnson & Johnson, Roche, Pfizer, and AstraZeneca

13,337 Shares in Johnson & Johnson $JNJ Purchased by Greg Jennings LLC

Johnson & Johnson (NYSE:JNJ) Stock Rating Cut to Hold at Erste Group Bank - Daily Political

Johnson & Johnson (NYSE:JNJ) Shares Climb 2.2% - Here's What Happened

2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)

Dow leads Wall Street higher, investors focus on healthcare stocks

Lawsuit accuses Essity, Edgewell, J&J of violating PFAS ban in California

Healthcare Stocks To Research - October 20th - Markets Daily

Johnson & Johnson (JNJ): Are Its Medical Device Deals Paying Off?

J&J Launches Faster Coronary IVL Catheter, Highlights Abu Dhabi Surgical Collaboration

Johnson & Johnson (NYSE:JNJ) Stock Jumps 2.2% - Still a Buy? - Daily Political

What Capital Group Core Balanced ETF (CGBL) Bought: JNJ Leads on Oct. 16

Pharmaceutical Stocks To Consider - October 20th - Daily Political

Multiple Myeloma Pipeline 2026: Who Is Leading the Race? Top Companies and Emerging Therapies to Watch by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics | ABNewswire

Best Pharmaceutical Stocks To Keep An Eye On - October 19th - Markets Daily

Johnson & Johnson's Dividend Machine Is Running. Can Earnings Keep Up?

Johnson & Johnson Reports 48-Week Tremfya Results in Phase 3 Crohn's Disease Fistula Study

Ds vs. Dividend Stocks: One Protects Your Principal, the Other Could Grow Your Income

Is Johnson & Johnson (JNJ) Undervalued Following Its Latest Oncology Update?

Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula | Morningstar

Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead

Johnson & Johnson $JNJ Stock Sold by PineStone Asset Management Inc.

Johnson & Johnson $JNJ Stock: 1834 Investment Advisors Co. Reduces Holdings

What Does Johnson & Johnson (JNJ) News Mean For Its Growth Case? - Simply Wall St News

Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats | Valuespectrum.com

Best Healthcare Stocks To Keep An Eye On - October 18th - Stock Observer

Healthcare Stocks To Consider - October 15th - Markets Daily

Johnson & Johnson $JNJ Stock: Goelzer Investment Management Inc. Decreases Holdings

Johnson & Johnson $JNJ Stock: Cyndeo Wealth Partners LLC Lowers Position

Johnson & Johnson $JNJ Position Lessened by Banque Pictet & Cie SA

Johnson & Johnson (NYSE:JNJ) Stock Gets Price Target Reduction from Morgan Stanley - Zolmax

JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law | Morningstar

Healthcare Stocks To Consider - October 17th - Markets Daily

Johnson & Johnson $JNJ Stock Sold by First Merchants Corp - Markets Daily

Johnson & Johnson $JNJ Stock: Guyasuta Investment Advisors Inc. Decreases Stake - Markets Daily

Community Financial Services Group LLC Buys 3,745 Shares of Johnson & Johnson $JNJ - Stock Observer

Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy. - AOL

 Week Ahead: Inflation Data from U.S., Canada, and U.K. Take Centre Stage

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

Week Ahead: BoC and ECB Interest Rate Decisions in Focus This Week

Week ahead: ECB set to cut as Wall Street earnings season gathers pace

Week ahead: US earnings season kicks off, ECB hold expected

Europe Tries to Ride on US Coat-tails

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk